---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-029169"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2023-08-16T23:59:59+00:00"
generated_at: "2026-06-11T08:35:50.225087+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vivos Q2 revenue falls to $3.4M (-19% YoY); net loss narrows 21% but now expects added financing

## Summary
- Revenue $3.4M, down 19% YoY from $4.2M; gross profit $2.1M (62% margin).
- Net loss reduced by $1.5M (21% YoY) reflecting cost cuts.
- Operating expenses cut 31% YoY ($2.9M reduction).
- Cash $3.9M; now expects to need additional financing as sales growth stalled.
- Patients treated ~40,000 (up from ~28,000); DSO pilots and first DME distribution deal signed.

## SEC filing metadata
- accession: 0001493152-23-029169
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2023-08-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315223029169/0001493152-23-029169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315223029169/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-029169
- JSON: https://secwatch.observer/filing/0001493152-23-029169.json
- Plain text: https://secwatch.observer/filing/0001493152-23-029169.txt

## Key facts
- Earnings Releases
  Vivos Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $3.4 million.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $3.4 million
  - Result: reported results
  source text: reported financial results and operating highlights for the second quarter and six months ended June 30, 2023. Second Quarter 2023 Financial and Operating Summary ● Revenue was $3.4 million for the second quarter of 2023 and $7.3 million for the six months ended June 30, 2023, compared to $4.2 million and $7.8 million for the three and six months ended June 30,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315223029169/0001493152-23-029169-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.